SI1519939T1 - N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba - Google Patents

N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba

Info

Publication number
SI1519939T1
SI1519939T1 SI200331767T SI200331767T SI1519939T1 SI 1519939 T1 SI1519939 T1 SI 1519939T1 SI 200331767 T SI200331767 T SI 200331767T SI 200331767 T SI200331767 T SI 200331767T SI 1519939 T1 SI1519939 T1 SI 1519939T1
Authority
SI
Slovenia
Prior art keywords
compounds
disorders
effects
significant
compositions
Prior art date
Application number
SI200331767T
Other languages
English (en)
Inventor
Balwinder S Bhatti
Craig H Miller
Jeffrey D Schmitt
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of SI1519939T1 publication Critical patent/SI1519939T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SI200331767T 2002-07-05 2003-06-27 N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba SI1519939T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39433702P 2002-07-05 2002-07-05
EP03739358A EP1519939B9 (en) 2002-07-05 2003-06-27 N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
PCT/US2003/020524 WO2004005293A2 (en) 2002-07-05 2003-06-27 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
SI1519939T1 true SI1519939T1 (sl) 2010-04-30

Family

ID=30115707

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331767T SI1519939T1 (sl) 2002-07-05 2003-06-27 N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba

Country Status (24)

Country Link
US (5) US6956042B2 (sl)
EP (2) EP1519939B9 (sl)
JP (2) JP4749715B2 (sl)
KR (1) KR101052287B1 (sl)
CN (1) CN100564381C (sl)
AT (1) ATE451373T1 (sl)
AU (1) AU2003245753B2 (sl)
BR (1) BR0312414A (sl)
CA (1) CA2491506C (sl)
CY (1) CY1110291T1 (sl)
DE (1) DE60330456D1 (sl)
DK (1) DK1519939T5 (sl)
EA (1) EA009789B1 (sl)
ES (1) ES2355157T3 (sl)
HK (1) HK1082951A1 (sl)
IL (1) IL165829A0 (sl)
MX (1) MXPA05000370A (sl)
NO (1) NO330130B1 (sl)
NZ (3) NZ537214A (sl)
PL (1) PL374434A1 (sl)
PT (1) PT1519939E (sl)
SI (1) SI1519939T1 (sl)
WO (1) WO2004005293A2 (sl)
ZA (1) ZA200500070B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9098297B2 (en) * 1997-05-08 2015-08-04 Nvidia Corporation Hardware accelerator for an object-oriented programming language
US6480205B1 (en) 1998-07-22 2002-11-12 Nvidia Corporation Method and apparatus for occlusion culling in graphics systems
US6844880B1 (en) 1999-12-06 2005-01-18 Nvidia Corporation System, method and computer program product for an improved programmable vertex processing model with instruction set
US7209140B1 (en) 1999-12-06 2007-04-24 Nvidia Corporation System, method and article of manufacture for a programmable vertex processing model with instruction set
DK1519939T5 (da) * 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
KR20070043008A (ko) * 2004-08-20 2007-04-24 타가셉트 인코포레이티드 중독 치료에서 ｎ-아릴 디아자스피라사이클릭 화합물의용도
JP2008513482A (ja) * 2004-09-20 2008-05-01 ターガセプト，インコーポレイテッド ニコチン性コリン作動性受容体活性を有するアザスピロアルケンおよびアザピロアルカン
WO2006058294A2 (en) * 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
MX2009002922A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
MX2009002919A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.
US7638526B2 (en) 2006-09-15 2009-12-29 Schering Corporation Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2712141A1 (en) * 2008-01-15 2009-07-23 Targacept, Inc. Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers
WO2009097405A2 (en) * 2008-01-30 2009-08-06 Neurogen Corporation Compounds and methods for preparing diazaspiro derivatives
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
EP2296640A1 (en) 2008-05-12 2011-03-23 Targacept Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010045417A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
CN101875658B (zh) * 2009-04-28 2013-01-09 上海药明康德新药开发有限公司 3-羰基-2,8-二氮杂螺[4.5] 癸烷-8-羧酸叔丁酯的制备方法
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
JP2016506961A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR20150110784A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2015066371A1 (en) * 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3119774A1 (en) 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
ES2893289T3 (es) 2014-08-28 2022-02-08 Asceneuron Sa Inhibidores de glucosidasa
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
PT3402784T (pt) 2016-01-13 2020-06-18 Gruenenthal Gmbh Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4,5]-decano
HUE051642T2 (hu) 2016-01-13 2021-03-01 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok
CN108779075B (zh) 2016-01-13 2022-01-11 格吕伦塔尔有限公司 3-(羧基甲基)-8-氨基-2-氧代-1，3-氮杂-螺-[4.5]-癸烷衍生物
EP3722284A1 (en) 2016-01-13 2020-10-14 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
CA3014572C (en) 2016-02-25 2023-10-03 Asceneuron S.A. Acid addition salts of piperazine derivatives
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201990425A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
IL286107B1 (en) 2016-08-01 2024-05-01 Aptinyx Inc Spiro-lactam NMDA receptor modulators and their uses
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CN110267961A (zh) * 2017-02-06 2019-09-20 詹森药业有限公司 Oga抑制剂化合物
CN107312011A (zh) * 2017-06-29 2017-11-03 上海药明康德新药开发有限公司 外消旋‑7‑叔丁氧基羰基‑1‑氧亚基‑2,7‑二氮杂螺壬烷‑4‑羧酸的合成方法
US20200369611A1 (en) * 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
EP3694510A4 (en) 2017-10-10 2021-06-30 Biogen Inc. SPIRO DERIVATIVE PREPARATION PROCESS
WO2019084075A1 (en) * 2017-10-24 2019-05-02 The Trustees Of The University Of Pennsylvania DOPAMINE RECEPTOR SELECTIVE ANTAGONISTS AND METHODS OF USING THE SAME
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
EP3758695A4 (en) 2018-02-28 2021-10-06 The Trustees Of The University Of Pennsylvania POLY (AD-RIBOSE) DEPENDENT CYTOTOXIC AGENTS LOW AFFINITY POLYMERASE-1
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
EP4161656A4 (en) 2020-06-05 2024-06-19 Kinnate Biopharma Inc INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
CN115181023B (zh) * 2022-05-17 2023-07-28 东华理工大学 螺环活性增塑剂及其制备方法
CN117865913A (zh) * 2024-01-10 2024-04-12 山东金特安全科技有限公司 一种呋虫胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4665079A (en) * 1984-02-17 1987-05-12 Warner-Lambert Company Antibacterial agents
NL8401907A (nl) * 1983-06-27 1985-01-16 Sandoz Ag Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden.
BE900003A (fr) * 1983-06-27 1984-12-27 Sandoz Sa Derives du spirosuccinimide utilisables comme medicaments.
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
DE3930262A1 (de) 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
US5852601A (en) * 1991-09-09 1998-12-22 Network Equipment Technologies, Inc. Method and apparatus for reactive congestion control in an asynchronous transfer mode (ATM) network
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
EP0842172A1 (en) 1995-06-29 1998-05-20 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
WO1999021834A1 (en) 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
PT970957E (pt) * 1998-06-12 2002-02-28 Hoffmann La Roche Derivados de diaza-espiro¬3,5|nonamo
AU1244001A (en) 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
ATE250603T1 (de) 2000-03-07 2003-10-15 Us Gov Health & Human Serv 1,8-naphthalimid imidazo(4,5,1-de)acridone mit antitumorwirkung
WO2001066546A1 (fr) * 2000-03-09 2001-09-13 Mitsubishi Pharma Corporation Composes spiro, leur procede de preparation et leur utilisation comme medicaments
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DK1519939T5 (da) * 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf

Also Published As

Publication number Publication date
JP4749715B2 (ja) 2011-08-17
ATE451373T1 (de) 2009-12-15
CN1665818A (zh) 2005-09-07
EA200500164A1 (ru) 2005-06-30
WO2004005293A2 (en) 2004-01-15
KR101052287B1 (ko) 2011-07-27
US6956042B2 (en) 2005-10-18
MXPA05000370A (es) 2005-04-19
NZ537214A (en) 2007-08-31
HK1082951A1 (en) 2006-06-23
US7375110B2 (en) 2008-05-20
US20080214591A1 (en) 2008-09-04
PL374434A1 (en) 2005-10-17
IL165829A0 (en) 2006-01-15
EP2078718A1 (en) 2009-07-15
US20040067930A1 (en) 2004-04-08
CA2491506C (en) 2011-04-26
CY1110291T1 (el) 2015-01-14
US20110105548A1 (en) 2011-05-05
EP1519939B1 (en) 2009-12-09
AU2003245753A1 (en) 2004-01-23
US20060217406A1 (en) 2006-09-28
KR20050024453A (ko) 2005-03-10
WO2004005293A3 (en) 2004-05-13
CN100564381C (zh) 2009-12-02
JP2011088896A (ja) 2011-05-06
BR0312414A (pt) 2005-05-10
AU2003245753B2 (en) 2009-12-24
NO330130B1 (no) 2011-02-21
DK1519939T3 (da) 2010-04-12
CA2491506A1 (en) 2004-01-15
ES2355157T9 (es) 2011-10-07
EP1519939A2 (en) 2005-04-06
EP1519939B9 (en) 2011-04-06
ES2355157T3 (es) 2011-03-23
ZA200500070B (en) 2005-11-01
NZ551552A (en) 2008-03-28
US7923559B2 (en) 2011-04-12
US20050272739A1 (en) 2005-12-08
NZ566367A (en) 2009-04-30
EA009789B1 (ru) 2008-04-28
DE60330456D1 (de) 2010-01-21
US7291731B2 (en) 2007-11-06
JP2005536491A (ja) 2005-12-02
DK1519939T5 (da) 2011-01-24
PT1519939E (pt) 2010-02-10
NO20050012L (no) 2005-04-01

Similar Documents

Publication Publication Date Title
HK1082951A1 (en) N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
WO2006023630A3 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
MX2009004801A (es) Amidas de diazabicicloalcanos selectivas de subtipo de receptor nicotinico de acetilcolina.
RS65704A (en) Aza-arylpiperazines
IL295536B2 (en) Specific tryptamines for use in the treatment of mood disorders
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
DK1678172T3 (da) Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
TW200736251A (en) Aryl-isoxazol-4-yl-imidazole derivatives
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
TW200716547A (en) Piperidin-4-yl-amide derivatives
IL192287A0 (en) Pharmaceutical compositions and methods for use
MX2009010630A (es) Derivados de azabicicloalcano selectivos de sub-tipo.
TW200510378A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
TW200607802A (en) 3-piperidinylisochroman-5-ols as dopamine agonists
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
WO2007009012A3 (en) Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
UA81405C2 (en) Substituted pyridinones as modulators of p38 map kinase
IL188723A0 (en) Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists